Boehringer Ingelheim Announces The Launch Of CENTRAGARD™ (eprinomectin and praziquantel transdermal solution), Innovative Internal Parasite Protection For Cats
Retrieved on:
Monday, August 20, 2018
Today, Boehringer Ingelheim announces the launch of CENTRAGARD (eprinomectin and praziquantel transdermal solution), a monthly heartworm disease preventive product for cats that is applied topically.
Key Points:
- Today, Boehringer Ingelheim announces the launch of CENTRAGARD (eprinomectin and praziquantel transdermal solution), a monthly heartworm disease preventive product for cats that is applied topically.
- CENTRAGARD is also approved to treat and control three of the most common intestinal parasites of cats -- hookworms, roundworms, and tapeworms.
- It is the first, and only, product to protect against this spectrum of parasites in an easy-to-use transdermal formulation.
- Heartworm disease is a serious and potentially fatal disease that can affect dogs, cats, and other animals.